These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26676096)

  • 1. Target Identification of Compounds from a Cell Viability Phenotypic Screen Using a Bead/Lysate-Based Affinity Capture Platform.
    Tang H; Duggan S; Richardson PL; Marin V; Warder SE; McLoughlin SM
    J Biomol Screen; 2016 Feb; 21(2):201-11. PubMed ID: 26676096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying compound efficacy targets in phenotypic drug discovery.
    Schirle M; Jenkins JL
    Drug Discov Today; 2016 Jan; 21(1):82-89. PubMed ID: 26272035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated drug discovery by rapid candidate drug identification.
    Bergström F; Lindmark B
    Drug Discov Today; 2019 Jun; 24(6):1237-1241. PubMed ID: 30946980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation phenotypic screening.
    Warchal SJ; Unciti-Broceta A; Carragher NO
    Future Med Chem; 2016 Jul; 8(11):1331-47. PubMed ID: 27357617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens.
    Bornot A; Blackett C; Engkvist O; Murray C; Bendtsen C
    J Biomol Screen; 2014 Jun; 19(5):696-706. PubMed ID: 24441646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
    Roy A; McDonald PR; Sittampalam S; Chaguturu R
    Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic screens targeting neurodegenerative diseases.
    Zhang M; Luo G; Zhou Y; Wang S; Zhong Z
    J Biomol Screen; 2014 Jan; 19(1):1-16. PubMed ID: 23958650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoproteomic-enabled phenotypic screening.
    Conway LP; Li W; Parker CG
    Cell Chem Biol; 2021 Mar; 28(3):371-393. PubMed ID: 33577749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of selection bias on the evaluation of clusters of chemical compounds in the drug discovery process.
    Alonso A; Milanzi E; Molenberghs G; Buyck C; Bijnens L
    Pharm Stat; 2015; 14(2):129-38. PubMed ID: 25420717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of drug candidates and repurposing opportunities through compound-target interaction networks.
    Cichonska A; Rousu J; Aittokallio T
    Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enrichment analysis for discovering biological associations in phenotypic screens.
    Polyakov VR; Moorcroft ND; Drawid A
    J Chem Inf Model; 2014 Feb; 54(2):377-86. PubMed ID: 24437550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of antibacterial discovery revisited.
    Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
    Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity.
    Sukuru SC; Jenkins JL; Beckwith RE; Scheiber J; Bender A; Mikhailov D; Davies JW; Glick M
    J Biomol Screen; 2009 Jul; 14(6):690-9. PubMed ID: 19531667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell and small animal models for phenotypic drug discovery.
    Szabo M; Svensson Akusjärvi S; Saxena A; Liu J; Chandrasekar G; Kitambi SS
    Drug Des Devel Ther; 2017; 11():1957-1967. PubMed ID: 28721015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The discovery process in the pharmaceutical industry].
    Scatton B
    J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to avoid rediscovering the known.
    Kuo LC
    Methods Enzymol; 2011; 493():159-68. PubMed ID: 21371591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.